Why DaVita Inc. (DVA) stock moved
No significant move on Nov 16, 2026 (−0.2%, close-to-close). Latest notable session: Nov 12, 2026.
Why DaVita Inc. (DVA) fell 5.1% on November 12, 2026
DaVita Inc. (DVA) fell 5.1% on November 12, 2026, closing at $174.07 versus $183.50 the prior session (close-to-close, from daily closes). Volume remained subdued at 0.56x expected levels for this stage of the session, suggesting limited conviction behind the decline. Source: defenseworld.net.
DaVita fell 4.58% to $175.09 intraday, retreating from recent strength above its 200-day moving average (per defenseworld.net). Volume remained subdued at 0.56x expected levels for this stage of the session, suggesting limited conviction behind the decline.
What to watch next: DaVita's Q4 2026 earnings release on February 1, 2027, and whether the stock reclaims or breaks below the 200-day moving average ahead of that date.
Earlier sessions that moved DVA
- −3.4%On the same day, a law firm initiated a securities investigation into DaVita for potential federal violations, and the company presented at the UBS Global Healthcare Conference discussing dialysis growth projections and drug cost savings offsetting 2027 reimbursement headwinds.
- −3.0%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +5.8%We checked news, earnings, analyst updates, and filings — no company-specific catalyst was found.
- −3.0%DaVita reported Q3 earnings today with an accompanying 8-K filing, triggering a sharp 6.35% intraday decline from $193.31 to $181.03 (MarketBeat earnings call transcript, SEC 8-K filing).
- +5.1%Driven by investor litigation investigation announcement from Pomerantz Law Firm (PR Newswire).
- +5.3%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −6.2%As traders repositioned ahead of Q3 earnings scheduled for October 29, 2026. Read the October 20, 2026 analysis →
- +4.7%After the company presented seven clinical studies at ASN Kidney Week 2026 focused on dialysis innovation and patient outcomes.
- −4.6%DaVita Inc. (DVA ) stock is down roughly 4.1% today to about $175.64 per share, driven by a continuation of profit-taking and broader healthcare sector underperformance following its recent post-earnings volatility.
- −5.6%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +4.3%We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
DaVita Inc. (DVA) shares fell 0.2% to $174.22 as of November 17, 2026, a slight decline from the prior close of $174.56. BestStocks flagged the session as a major change for DVA. Below, we break down what changed for DVA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
DVA fell 0.2% to $174.22
DVA fell 0.2% in its latest session, moving from $174.56 to $174.22.
What it means for DaVita Inc. investors
For DaVita Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 0.2%; DaVita fell 4.58% to $175.09 intraday, retreating from recent strength above its 200-day moving average (per defenseworld.net). Wall Street's consensus price target sits at $238.50, implying +36.9% upside from $174.22. BestStocks rates the overall signal quality weak (32/100). With earnings roughly 76 days out, the next report is the most likely near-term test of the move.
DVA price reaction
DVA last traded at $174.22, down $0.34 (-0.19%) from the previous close of $174.56. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $174.07 and $194.82, and it currently sits about 1% of the way up that band.
Bullish and bearish analyst opinions on DaVita Inc. (DVA)
The consensus analyst price target on DaVita Inc. (DVA) is $238.50, 36.9% above the recent $174.22. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on DVA line up.
The bullish case
- Wall Street's consensus price target of $238.50 implies +36.9% upside from $174.22.
- The Street's most bullish target is $287.00 (+64.7%).
- Positive price momentum.
The bearish case
- Negative session, down 0.2%.
- DaVita fell 4.58% to $175.09 intraday, retreating from recent strength above its 200-day moving average (per defenseworld.net).
- DaVita reported Q3 earnings today with an accompanying 8-K filing, triggering a sharp 6.35% intraday decline from $193.31 to $181.03 (MarketBeat earnings call transcript, SEC 8-K filing).
- DaVita fell 4.18% to $179.18 as traders repositioned ahead of Q3 earnings scheduled for October 29, 2026.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 17, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for DVA
In-depth DVA event analyses
Frequently asked questions about DVA
Why did DaVita Inc. (DVA) stock move?
DaVita Inc. (DVA) fell 5.1% on November 12, 2026, closing at $174.07 versus $183.50 the prior session (close-to-close, from daily closes). Volume remained subdued at 0.56x expected levels for this stage of the session, suggesting limited conviction behind the decline. Source: defenseworld.net.
How much did DVA stock fall?
DVA lost 0.19% ($0.34) versus the prior close of $174.56, last trading at $174.22 on 0.7× average volume.
When is DaVita Inc.'s next earnings date?
DVA's next earnings report is estimated for 2027-02-01 — about 76 days away.
What is the analyst price target for DVA?
The consensus analyst price target for DVA is $238.50, about 36.9% above the current $174.22. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.
How BestStocks tracks DVA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared DVA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for DVA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 17, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
